Mycenax Biotech Inc. (TPEX:4726)
Taiwan · Delayed Price · Currency is TWD 24.40
-0.10 (-0.41%)
Jul 30, 2026, 9:56 AM CST
Mycenax Biotech Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 815.34 | 740.24 | 683.92 | 652.62 | 732.28 | 774.27 |
Revenue Growth | 12.39% | 8.23% | 4.80% | -10.88% | -5.42% | 16.37% |
Gross Profit Gross Profit Growth | -161.98 | -181.41 | -241.36 | -375.19 | -113.67 | 137.61 |
Operating Income Operating Income Growth | -384.83 | -403.84 | -461.54 | -602.1 | -445 | -85.33 |
Net Income Net Income Growth | -436.48 | -448.63 | -467.13 | -682.85 | -453.63 | -89.86 |
Earnings Per Share EPS Growth | -2.14 | -2.17 | -2.27 | -3.32 | -2.74 | -0.61 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Taiwan Taiwan Growth | 158.56 | 180.22 | 267.07 | 156.13 | 278.17 | 101.36 |
Asia Asia Growth | 589.18 | 494.11 | 369.87 | 493.77 | 325.58 | 405.59 |
America America Growth | 18.08 | 20.1 | 6.56 | 2.72 | 7.07 | 73.23 |
Europe Europe Growth | 49.53 | 45.81 | 40.44 | - | 121.46 | 194.1 |
Total Total Growth | 815.34 | 740.24 | 683.92 | 652.62 | 732.28 | 774.27 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 216.32 | 224.55 | 276.87 | 667.69 | 1,339 | 286.93 |
Total Debt Total Debt Growth | 1,183 | 1,072 | 883.39 | 726.28 | 955.85 | 744.64 |
Net Cash (Debt) Net Cash Growth | -967.08 | -847.35 | -606.53 | -58.59 | 383.63 | -457.72 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -4.27 | -4.09 | -2.94 | -0.29 | 2.32 | -3.08 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -67.55 | -27.24 | -191.68 | -131.18 | -150.19 | -146.23 |
Capital Expenditures CapEx Growth | -97.16 | -88.54 | -330.43 | -295.63 | -626.94 | -1,098 |
Free Cash Flow Free Cash Flow Growth | -164.71 | -115.78 | -522.11 | -426.81 | -777.12 | -1,244 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -19.87% | -24.51% | -35.29% | -57.49% | -15.52% | 17.77% |
Operating Margin | -47.20% | -54.55% | -67.48% | -92.26% | -60.77% | -11.02% |
Pretax Margin | -54.55% | -61.35% | -68.66% | -104.81% | -63.21% | -11.30% |
Profit Margin | -53.53% | -60.61% | -68.30% | -104.63% | -61.95% | -11.61% |
FCF Margin | -20.20% | -15.64% | -76.34% | -65.40% | -106.12% | -160.71% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 11.97 | 11.97 | 11.97 | 11.97 | 11.97 |
PS Ratio | 6.23 | 8.85 | 13.11 | 11.26 | 10.51 | 7.51 |